Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/14/2012 | 06:55pm CET

--FDA concludes safety review of MS drug Gilenya

--FDA advises against use in certain heart and stroke patients

--FDA says no clear link between Gilenya and cardiovascular deaths

(Updates with additional background on EMA review starting in seventh paragraph and information on experimental Biogen Idec MS drug.)

 
   By Jennifer Corbett Dooren 
   Of  
 

The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.

The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.

The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily.

As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear."

The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines.

Europe's drug regulator, the European Medicines Agency, last month requested stronger safety warnings for Gilenya after the agency concluded its review of the drug.

Gilenya is currently the only oral MS drug on the market but its sales prospects have been clouded by recent safety concerns. It was approved in the U.S. in 2010 and has been available in Europe since 2011.

The product is designed to treat patients with the relapsing form of MS, which is a progressive disease that involves damage to the nerves controlling muscles and vision.

The FDA is currently reviewing another oral MS drug from Biogen Idec Inc. (BIIB) called BG-12 that is designed to work through a different mechanism than Gilenya. Biogen Idec last week announced that the FDA accepted BG-12's new drug application for a standard 10-month review, which sets an agency decision deadline of about Dec. 28.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
03:20p NOVARTIS : Serelaxin Setback Puts Focus On Entresto
07:16a NOVARTIS : Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multi..
03/22 Global Inhalation & Nasal Spray Generic Drugs Market- Teva, Allergan PLC, Cip..
03/22 NOVARTIS` : Cosentyx is first and only IL-17A inhibitor to potentially modify th..
03/22 NOVARTIS : provides update on Phase III study of RLX030 (serelaxin) in patients ..
03/21 IMS HEALTH : Glenmark gets tentative nod from USFDA for Fingolimod capsules
03/21 NOVARTIS : ' Cosentyx is first and only IL-17A inhibitor to potentially modify t..
03/20 NOVARTIS : New analysis shows Novartis Entresto improves glycemic control in red..
03/18 NOVARTIS : New analysis shows Novartis Entresto improves glycemic control in red..
03/18 NOVARTIS : New analysis shows Novartis Entresto improves glycemic control in red..
More news
Sector news : Pharmaceuticals - NEC
02:04p J&J latest to suspend ads from YouTube over offensive videos
11:53a TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/22 Serelaxin Setback Puts Focus On Entresto
03/22 BIOLINERX : Update And Preview Of The Company's Q4 And FY 2016 Financial Results..
03/22 Novartis' serelaxin flunks late-state heart failure study; shares ease a frac..
03/21 ABBVIE : Good For Value, Good For Growth
03/21 UPCOMING EVENTS : Alder's Migraine Test, Paratek's Antibiotic
Advertisement
Financials ($)
Sales 2017 48 429 M
EBIT 2017 11 388 M
Net income 2017 7 506 M
Debt 2017 15 034 M
Yield 2017 3,81%
P/E ratio 2017 22,47
P/E ratio 2018 19,82
EV / Sales 2017 4,32x
EV / Sales 2018 4,11x
Capitalization 194 072 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 80,4 $
Spread / Average Target 8,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG0.47%194 072
JOHNSON & JOHNSON9.59%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.6.13%205 273
MERCK & CO., INC.7.86%174 344
SANOFI7.63%115 490
More Results